¹ **Time-to-event estimation of birth year prevalence trends:**

² **a method to enable investigating the etiology of**

³ **childhood disorders including autism**

- 4 Alexander G. MacInnis^{1*}
- 5
- 6 ¹ Independent researcher, Mountain View, California, United States of America
- 7 * Corresponding author
- 8 Email: a.macinnis@alumni.stanford.edu (AGM)

Time-to-Event Prevalence Estimation

Abstract

 Measures of incidence are essential for investigating etiology. For congenital diseases and disorders of early childhood, birth year cohort prevalence serves the purpose of incidence. There is uncertainty and controversy regarding the birth prevalence trend of childhood disorders such as autism and intellectual disability because changing diagnostic factors can affect the rate and timing of diagnosis and confound the true prevalence trend. The etiology of many developmental disorders is unknown, and it is important to investigate. This paper presents a novel method, Time-to-Event Prevalence Estimation (TTEPE), to accurately estimate the time trend in birth prevalence of childhood disorders correctly adjusted for changing diagnostic factors. There is no known existing method that meets this need. TTEPE is based on established time-to- event (survival) analysis techniques. Input data are rates of initial diagnosis for each birth year cohort by age or, equivalently, diagnostic year. Diagnostic factors form diagnostic pressure, i.e., the probability of diagnosing cases, which is a function of diagnostic year. Changes in diagnostic criteria may also change the effective prevalence at known times. A discrete survival model predicts the rate of initial diagnoses as a function of birth year, diagnostic year, and age. Diagnosable symptoms may develop with age, affecting the age of diagnosis, so TTEPE incorporates eligibility for diagnosis. Parameter estimation forms a non-linear regression using general- purpose optimization software. A simulation study validates the method and shows that it produces accurate estimates of the parameters describing the trends in birth prevalence and diagnostic pressure. The paper states the assumptions underlying the

Time-to-Event Prevalence Estimation

- analysis and explores optional additional analyses and potential deviations from
- assumptions. TTEPE is a robust method for estimating trends in true case birth
- prevalence controlled for diagnostic factors and changes in diagnostic criteria under
- certain specified assumptions.

Keywords

- Birth year prevalence; birth year cohort; incidence; time-to-event; survival analysis;
- diagnostic factors; diagnostic pressure; non-linear regression; autism; intellectual
- disability; childhood disorders; developmental disorders

Introduction

 In epidemiology, incidence - the rate of new cases - is a fundamentally important metric for estimating causal associations of time-varying risk factors with rates of a disorder [1,2]. Incidence is different from prevalence, which is the proportion of a defined population with the disorder at a defined time. For some disorders including congenital diseases and developmental disorders such as autism and intellectual disability, birth year cohort prevalence is used instead of incidence [2,3] because disorder incidence is indistinguishable from birth prevalence, and diagnosis may occur later if at all. Sometimes "incidence" is used to mean the rate of incident diagnoses rather than true incidence, which refers to a disorder. While this usage is understandable because observations inherently represent diagnosis and identification, the difference can be

Time-to-Event Prevalence Estimation

 was this caused by changes in actual birth prevalence, the probability of diagnosing cases, diagnostic criteria affecting prevalence, or some combination of these factors? It

Time-to-Event Prevalence Estimation

 is challenging to disentangle these effects, and there is no known existing method capable of doing so correctly.

Literature Review

 There are many studies on the prevalence of developmental disorders, yet very few of them directly address birth year prevalence trends and very few address methods of adjustment for diagnostic factors. The series of reports from the US Centers for Disease Control and Prevention's (CDC) Autism and Developmental Disabilities Monitoring Network (ADDM) [5-13] estimate the prevalence of autism among children who were eight years old at each even-numbered year 2000 through 2016. Each report describes the prevalence of a single year birth cohort, subject to rounding, born eight years before the respective study year. The set of reports represents the trend in birth year prevalence, but the reports describe the findings as simply "prevalence," and do not discuss birth year prevalence or similar names. The ADDM reports suggest that the observed increases in (birth year) prevalence may result from various factors, including changing composition of study sites and geographic coverage, improved awareness, and changes in diagnostic practice and availability of services. However, they do not suggest methods to quantify such effects or to adjust for them. Croen [14] examined birth year prevalence trends in autism and mental retardation in California for birth years 1987 to 1994. They concluded that the data and methods available were insufficient to determine how much of the observed increase reflected an increase in true birth prevalence. Hansen [15] recommends using the cumulative incidence of diagnoses of childhood psychiatric disorders for each 1-year birth cohort as a measure of risk. They

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

Campbell [18] and McKenzie [26] both point out that various factors could potentially

affect the rate of diagnoses without affecting the true case rate.

Overview

The primary aim of this work is to develop and specify a method to estimate birth

prevalence trends, correctly adjusted for trends in the set of diagnostic factors and

changes in diagnostic criteria. Armed with such a tool, researchers can quantify the

effects of the set of variable causal factors separately from those of the set of diagnostic

factors. Where covariates are available, investigators can estimate associations of birth

prevalence with a variety of population characteristics that may be causal or

explanatory.

This paper presents a novel statistical method called time-to-event prevalence

estimation (TTEPE). It uses time-to-event survival analysis to estimate the trend in true

birth year prevalence, correctly adjusted for changes in the set of diagnostic factors and

diagnostic criteria. It presents the derivation of the analytical method from first principles

and states all the underlying assumptions. A simulation study shows that the method

Time-to-Event Prevalence Estimation

- effectively separates and quantifies the birth year trend and the trend in the effects of
- diagnostic factors, producing accurate estimates.

Method of time-to-event prevalence estimation

(TTEPE)

Background

 Comparison of prevalence estimates across multiple studies generally is not suitable for informing tends in birth prevalence nor incidence [2]. Different prevalence estimates may use different mixes of birth years and ages, as well as numerous other possible differences between prevalence studies [27]. Many combinations of trends in birth prevalence and diagnostic factors could potentially explain observed prevalence trends. The Introduction section briefly describes the problems with age-period-cohort analyses. 170 Age (A), diagnostic year (DY), and birth year (BY) are exactly collinear, $DY = BY + A$, subject to rounding, which leads to unidentified estimates when using a linear predictor. Another reason is that the age distribution of diagnoses can differ for different solutions 173 of BY and DY, as shown below. It is challenging to estimate the age distribution correctly given the collinearity problem.

 Analysis of the cumulative incidence, to a consistent age, of diagnoses in each birth cohort comes closer to estimating the trend in true birth prevalence, but results are still

Time-to-Event Prevalence Estimation

- ambiguous. Here too, many combinations of trends in birth prevalence and diagnostic
- factors can produce similar trends in cumulative incidence.

Ambiguity in estimation

- How should one interpret a dataset that produces any one of the cumulative incidence
- curves illustrated in Fig 1? The figure represents synthetic data; some real-world data
- may be similar. Observed data might produce a curve resembling any one of the curves
- in the figure. An exponential curve with a coefficient of 0.1 fits all three plotted lines
- reasonably well. Does this represent a true increase in birth prevalence with a
- coefficient of 0.1? Does it result from an exponential increase in the effects of diagnostic
- factors, with no increase in birth prevalence? Perhaps a combination of both? The three
- similar cumulative incidence curves represent quite different possible explanations. How

 $-$ Beta P=0.08, Beta h=0.05

-Beta P=0.1, Beta h=0

to distinguish which one is correct?

Seta P=0, Beta h=0.134

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

208

209 **Fig 2**. Distribution of diagnoses in the first and last cohorts under three models. β_P is the

210 coefficient for birth prevalence; β_H is the coefficient for the effect of diagnostic factors. Red lines

211 with circles represent $\beta_P = 0.1$, $\beta_H = 0$; green lines with squares represent $\beta_P = 0.08$, $\beta_H = 0.5$;

Time-to-Event Prevalence Estimation

 If the disorder's complete cause is in place at birth, then the incidence of the disorder is indistinguishable from birth prevalence. In contrast, diagnosis occurs later, if at all. The incidence of diagnosis represents the combination of birth prevalence and delays and omissions in diagnoses.

One might consider controlling for diagnostic factors over time, for example, via

regression, but that is not sufficient to distinguish between alternative explanations.

Diagnostic factors are a function of time, and birth year prevalence is also a function of

time. As the Introduction states, controlling directly for diagnostic factors biases the

estimates of the main effect, typically towards zero, citing Schisterman [19] and

Rothman [2]. Schisterman recommends, "clearly stating a causal question to be

addressed, depicting the possible data generating mechanisms using causal diagrams,

and measuring indicated confounders." This paper directly addresses these issues.

Significance of birth year and diagnostic year

 Diagnostic factors only affect the diagnosis of cases when those cases exhibit diagnosable symptoms, referred to as being eligible for diagnosis. Diagnostic pressure is the probability of diagnosing eligible undiagnosed cases, and it is an effect of the combination of all diagnostic factors. The Introduction lists examples.

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

Fig 3. Directed Acyclic Graph Representing Year of Birth, Diagnostic Year and Age

Changes in diagnostic criteria can affect the threshold of symptoms that qualify case

status. Criteria changes may change the proportion of the cohort classified as cases,

i.e., the effective prevalence.

Development of the TTEPE method

The TTEPE method is based on the DAG of Fig 3 and modeling the age distribution of

initial diagnoses. The method avoids the identification problem associated with age-

period-cohort analysis, and it avoids the problem of inappropriate adjustment for

diagnostic factors.

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

314 given value of prevalence P , as shown in the Illustrative example section.

315 **Time-to-event analysis model**

316 The analysis model enables estimation of the temporal trend of birth prevalence P over 317 a range of cohorts, correctly adjusted for diagnostic pressure h . Both P and h can vary 318 with time. P is a function of birth year, and h is a function of diagnostic year. Estimation 319 of P adjusted for h requires estimating the time-based parameters of both P and h in 320 the time-to-event model and specifying or estimating the eligibility function E .

321

Time-to-Event Prevalence Estimation

328

329 Let h_{DY} be the diagnostic pressure at diagnostic year DY. $DY = BY + A$, subject to 330 rounding, so h_{DY} is equivalent to $h_{BY,A}$. Let P_{BY} be the case prevalence of birth year 331 cohort BY. Let $R_{BY,A}$ be the discrete risk set function of the population proportion of 332 eligible cases at risk of initial diagnosis at age A for birth year BY. TTEPE uses R rather 333 than a discrete survival function S to accommodate eligibility changing with age. Let E_A 334 be the discrete eligibility function, the proportion of cases that are eligible at age A , 335 bounded by $0 \le E \le 1$. At each age $A \ge 1$, $P \times (E_A - E_{A-1})$ is the incremental portion of 336 prevalent cases added to R due to changes in eligibility. For simplicity, assume E_A 337 increases monotonically, i.e., non-decreasing, meaning that cases do not lose eligibility 338 before diagnosis.

339

340 Kalbfleisch [31] gives background on general time-to-event theory and equations.

341

342 Consider three scenarios, differing by the characteristics of E_A . Here we write h_{DY} as 343 $h_{BY,A}$ to clarify the effect of A in $DY = BY + A$.

Time-to-Event Prevalence Estimation

and

$$
D_{BY,A} = P_{BY} \prod_{a=0}^{A-1} (1 - h_{BY,a}) h_{BY,A}
$$
 (1)

In all three scenarios in this paper, the survival function is:

Time-to-Event Prevalence Estimation

363
$$
S_{BY,A} = P_{BY} - \sum_{a=0}^{A-1} D_{BY,a}
$$
 (2)

364 The summation term is the cumulative incidence of initial diagnoses through age $A - 1$.

365

366 Scenario: Increasing E_A , E_0 < 1 and E_A increases monotonically with A. For $A = 0$,

367
$$
R_{BY,0} = E_0 P_{BY}
$$
 and $D_{BY,0} = E_0 P_{BY} h_{BY,0}$. For each $A \ge 1$, $R_{BY,A} = R_{BY,A-1} - D_{BY,A-1} + D_{BY,A-1}$

368 $(E_A - E_{A-1})P_{BY}$. The incremental increase of E_A causes an incremental increase in $R_{BY,A}$.

369 Then,

$$
B_{BY,A} = R_{BY,A}h_{BY,A} = (R_{BY,A-1} - D_{BY,A-1})h_{BY,A} + (E_A - E_{A-1})P_{BY}h_{BY,A}
$$
(3)

371 Equation (3) can be useful as a procedural definition. We can write equivalent

372 expressions for $R_{BY,A}$ and $D_{BY,A}$ as sums of expressions similar to equation (1), where 373 each summed expression describes the portion of P_{BY} that becomes eligible at each

374 age according to E_A . For $A \ge 1$,

375

376
$$
R_{BY,A} = \sum_{a=0}^{A-1} (E_a - E_{a-1}) P_{BY} \prod_{b=a}^{A-1} (1 - h_{BY,b})
$$

377

378
$$
D_{BY,A} = \sum_{a=0}^{A-1} (E_a - E_{a-1}) P_{BY} \prod_{b=a}^{A-1} (1 - h_{BY,b}) h_{BY,A}
$$
(4)

379

380 where E_{-1} is defined to be 0. E_A can be defined parametrically or non-parametrically. 381

Time-to-Event Prevalence Estimation

382 Scenario: Plateau E_A . E_A increases from $E_0 < 1$ and plateaus at $E_A = 1$ for $A \ge AE$,

383 where AE is the age of complete eligibility, $AE < M$, and M is the maximum age

384 included in the analysis. Equation (3) applies, noting that for $A > AE$, $(E_A - E_{A-1}) = 0$.

385 Equivalently, combine equation (2) with the fact that $E_{AE} = 1$ to obtain $R_{AE} = S_{AE} = P_{BY}$ –

386 $\sum_{a=0}^{AE-1} D_{BY,a}$, so

$$
D_{BY,AE} = R_{BY,AE} h_{BY,AE} = S_{BY,AE} h_{BY,AE} = (P_{BY} - \sum_{a=0}^{AE-1} D_{BY,a}) h_{BY,AE}
$$
(5)

388 and for $A > AE$,

389
$$
R_{BY,A} = S_{BY,A} = (P_{BY} - \sum_{a=0}^{AE-1} D_{BY,a}) \prod_{b=AE}^{A-1} (1 - h_{BY,b})
$$

390

391
$$
D_{BY,A} = (P_{BY} - \sum_{a=0}^{AE-1} D_{BY,a}) \prod_{b=AE}^{A-1} (1 - h_{BY,b}) h_{BY,A}
$$
 (6)

392

393 The scenario of increasing E_A is a general formulation and may not be needed in 394 practice. The plateau E_A scenario may be appropriate when external information, such 395 as the definition of the disorder, indicates the value of AE , or when investigators specify 396 AE based on estimates of E_A found using equation (4). Equations (5) and (6) do not 397 model E_A nor $D_{BY,A}$ for $A < AE$. Rather, they use the empirical values of $D_{BY,A}$ for $A <$ 398 AE.

Time-to-Event Prevalence Estimation

399 **Prevalence, cumulative incidence and censoring**

- 400 The case prevalence in each cohort is the cumulative incidence of initial diagnoses 401 through the last age of follow-up plus the censored portion. This assumes that any 402 difference in competing risks between cases and non-cases in the age range analyzed 403 is small enough to be ignored. This assumption is consistent with Hansen [15]. If the 404 rate of deaths of cases before initial diagnosis exceeds that of the entire population of 405 the cohort at the same ages, that excess would constitute a competing risk and would
- 406 reduce the estimated prevalence accordingly.
- 407

408 In all three scenarios of E_A , we can express P as a function of S and the cumulative

409 incidence $CI = \sum_{a=0}^{A-1} D_{BY,a}$ for $A > 0$, by rearranging equation (2) as $P = S_A + CI_{A-1}$.

410 Assuming that eligibility at the last age of follow-up $E_M = 1$, $S_M = R_M$. Then, $P = R_M +$

411 *CI_{M -1}* and $D_M = R_M h_M$. The censored proportion is $S_{M+1} = S_M - D_M$, which is equivalent

412 to $S_{M+1} = R_M - R_M h_M = R_M(1 - h_M)$. After estimating the model parameters, the

413 estimated censored proportion is $\widehat{S_{M+1}} = \widehat{R_M}(1 - \widehat{h_M})$.

414 **Illustrative example**

415 Fig 4 illustrates an example according to the plateau E_A scenario showing the

416 relationships between prevalence, diagnosis rates, the survival function, and cumulative

- 417 incidence CI with two different values of diagnostic pressure $h = 0.1$ and $h = 0.25$ and
- 418 prevalence $P = 0.01$. In this example, $E = 1$ for $A \ge AE = 3$ and h takes on one of two
- 419 constant values. The value of h determines the shapes of these functions vs. age. This

Time-to-Event Prevalence Estimation

420 example shows constant values of h purely for clarity, not as an assumption nor a

421 limitation of TTEPE.

422

423 **Fig 4.** Example of a survival process for two values of diagnostic pressure h.

424 The green lines S denote survival, the blue lines D denote the rate of diagnoses, and the red 425 lines CI denote cumulative incidence. The solid lines represent $h=0.1$, and the dotted lines 426 represent $h=0.25$.

427

428 As cases are diagnosed, S decreases and CI increases. R is not shown; $R = S$ for $A \geq$ 429 $AE = 3$. Only *D* is observable.

Time-to-Event Prevalence Estimation

Assumptions

- Several baseline assumptions enable TTEPE analysis. Some assumptions may be
- relaxed, as discussed below.
-
- 434 1. The eligibility function E_A under consistent diagnostic criteria is consistent across cohorts.
- 2. The diagnostic pressure applies equally to all eligible undiagnosed cases at any given diagnostic year.
- 3. The case prevalence under consistent diagnostic criteria within each cohort is

constant over the range of ages included in the analysis.

- 4. Case status is binary according to the applicable diagnostic criteria.
- 5. The discrete-time interval (e.g., one year) is small enough that the error
- introduced by treating the variable values as constant within each interval is
- negligible.
- 6. No false positives.
- 7. Data represent truly initial diagnoses.
- 8. Any difference in competing risks between cases and non-cases in the age range analyzed is small enough to be ignored.

- The assumption of a consistent eligibility function means that cases develop
- diagnosable symptoms as a function of age, and that function is the same for all cohorts

Time-to-Event Prevalence Estimation

451 under consistent diagnostic criteria. The section Changes in criteria affecting prevalence 452 discusses a separate effect that might make the eligibility function appear inconsistent.

453 **Estimating parameters**

- 454 TTEPE performs a non-linear regression that estimates the parameters of a model of
- 455 $D_{BY,A}$ using general-purpose optimization software. The model is based on equations (1)
- 456 through (6) selected based on the eligibility scenario. The model produces estimates
- 457 $\widehat{D_{BY,A}}$ from the parameters and independent variables, and the software finds the
- 458 parameter values that minimize a cost function cost(D, \hat{D}). One suitable implementation
- 459 of optimization software in the Python language is the curve fit() function in the SciPy
- 460 package (scipy.optimize.curve_fit in SciPy v1.5.2). Its cost function is $(D \widehat{D})^2$, so it
- 461 minimizes the sum of squared errors. Python software to perform this regression and
- 462 the simulations described below is available at OSF [28].
- 463

464 Investigators should choose which model equation to use based on knowledge or 465 estimates of the eligibility function E_A . The constant E_A scenario and equation (1) 466 assume that all cases are eligible from birth, which may not be valid for some disorders. 467 The validity of the assumption that all cases are eligible by a known age AE , i.e., the 468 plateau E_A scenario and equation (6), may be supported by either external evidence, 469 e.g., the definition of the disorder, or estimation of E_A . The least restrictive approach of 470 the increasing E_A scenario uses equation (4) to estimate E_A . Non-parametric estimates 471 $\widehat{E_A}$ can inform a choice of a parametric form of E_A . The value of E_A at the maximum age 472 studied M should be set to 1 to ensure the estimates are identifiable. If $E_A = 1$ for all $A \ge$

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

Changes in criteria affecting prevalence

509 *DY* included in the study. P_{BY} is the prevalence of cohort BY before the effect of any of

510 ${CF_{cy}}$. For each cohort BY, the effective prevalence $EP_{BY,A}$ at age A is

511
$$
EP_{BY,A} = P_{BY} \prod_{cy \le (BY+A)} CF_{cy}
$$
 (7)

512 where CF_0 , the value in effect before the first DY in the study, equals 1. The combination 513 of P_{BY} and the effects of all $\{CF_{cy} | cy \le BY + A\}$ determines the final effective prevalence of each cohort.

Time-to-Event Prevalence Estimation

515

516 For a given BY and increasing A, $BY + A$ crossing any cy causes a step-change in the 517 effective prevalence EP. Using a general formulation of eligibility E_A , per the increasing 518 E_A scenario and equation (3), and for clarity substituting $BY + A$ for DY, we obtain the 519 following. For $A = 0$, $R_{BY,0} = E_0 E P_{BY,0}$ and $D_{BY,0} = E_0 E P_{BY,0} h_{BY,0}$. For $A \ge 1$, 520 $R_{BY,A} = R_{BY,A-1} - D_{BY,A-1} + E_A(EP_{BY,A} - EP_{BY,A-1}) + (E_A - E_{A-1})EP_{BY,A}$

521 and

522
$$
D_{BY,A} = [R_{BY,A-1} - D_{BY,A-1} + E_A(EP_{BY,A} - EP_{BY,A-1}) + (E_A - E_{A-1})EP_{BY,A}]h_{DY}
$$
(8)

523 The term $EP_{BY,A} - EP_{BY,A-1}$ represents the change in the effective prevalence EP when 524 BY + A crosses one of $\{cy\}$. As each CF_{cy} takes effect at $cy = DY = BY + A$, the newly 525 effective CF_{cv} changes $EP_{BY,A}$ and R in all BY cohorts where cy corresponds to an age A 526 in the range of ages studied. These changes in R affect the rates of initial diagnoses D . 527 For cohorts born after cy , CF_{cy} applies to all ages.

528

529 The parameters of P_{BY} quantify the birth year prevalence controlled for diagnostic 530 criteria changes, which are represented by $\{CF_{cv}\}\$. In other words, P_{BY} is the cohort 531 prevalence that would have occurred if the initial criteria had been applied at all 532 diagnostic years included in the study.

533

534 To estimate the parameters, use a software model of equation (8) with optimization 535 software, as described in the previous section.

Time-to-Event Prevalence Estimation

Potential violations of assumptions

Time-to-Event Prevalence Estimation

 Fig 5. Example where observed diagnosis rates represent two unidentified subgroups with different values of diagnostic pressure. The red and green lines represent rates of diagnosis of the two subgroups. The solid black line shows the aggregate diagnosis rates. The dotted line 555 shows the exponential fit to the aggregate diagnosis rates. The age of eligibility $AE = 3$ in this example.

 Any imbalance of case prevalence between in-migration and out-migration to and from the region defining the population over the study period would violate the assumption of constant prevalence within each cohort.

If some in-migrating cases were diagnosed before in-migration and their subsequent re-

diagnoses in the study region were labeled as initial diagnoses, that would violate the

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

 at older ages. If false positives are more common at older ages, their effect may be even more obvious.

Model fit

 To ensure robust conclusions, investigators should test the model fit to ascertain both model correctness and parameter estimation accuracy. The model fits well if summary measures of the error are small and individual point errors are unsystematic and small 592 [33]. One can examine the fit both graphically and numerically. Plots of $D_{BY,A}$ vs. $\widehat{D_{BY,A}}$ at all ages for individual cohorts can illuminate any issues with fit, which might occur at only some cohorts or ages. Visualization of the model vs. data can expose aspects of the data that might not fit well in a model with few parameters, possibly suggesting a higher-order model or semi-parametric specifications.

598 If the model uses an assumed age of complete eligibility AE^* that differs from the true 599 value of AE represented by the data, model fit may be impaired, particularly if $AE[*].$ 600 As the Simulation study section shows, setting AE^{\ast} < AE can result in estimation errors. 601 Setting $AF^*\rightarrow AE$ tends not to impair model fit and may improve it in the case of non- homogeneous subgroups; see Fig 5. The presence of non-homogeneous subgroups may be evident from examining model fit.

 The chi-square test statistic, applied to the overall model, individual cohorts, and single ages across cohorts, is a numerical approach to assess absolute model fit. The p-value

Time-to-Event Prevalence Estimation

607 associated with the chi-square statistic utilizes observed and expected count values, not 608 proportions. The p-value incorporates the effect of the number of parameters in the 609 model via the degrees of freedom.

⁶¹⁰ **Simulation study**

611 We tested the TTEPE method via a simulation study where we know the ground truth of 612 all parameters, following the recommendations in Morris [34]. There are six pairs of 613 values of β_h and β_p , each ranging from 0 to 0.1 in steps of 0.02, and each pair sums to 614 0.1. In one parameter set, the prevalence increases as $e^{0.1\times BY}$ and diagnostic pressure 615 is constant; in another parameter set, the prevalence is constant and diagnostic 616 pressure increases as $e^{0.1\times DY}$; and the other four parameter sets represent various rates 617 of change of both variables. In all cases, $P = 0.01$ at the final BY, $h = 0.25$ at the final 618 DY, $AE = 3$, $M = 10$, and there are 20 successive cohorts. These simulations assume the 619 investigators know the correct value $AE^* = 3$ from either knowledge of the disorder or 620 estimation of E_A . The study synthesized each data model as real-valued proportions 621 without sampling and with binomial random sample generation of incident diagnoses. 622 For sampling, the population of each cohort is a constant 500,000. Monte Carlo 623 simulation of parameter estimation bias and model standard error (SE) used 1000 624 iterations of random data generation for each set of parameters. Parameter estimation 625 is as described above, implemented using the Python SciPy curve_fit() function.

626

Time-to-Event Prevalence Estimation

632

633 **Table 1. Simulation results of parameter optimization using real-valued**

634 **proportions with no sampling.**

636 20 successive cohorts.

637 β_P , β_h are coefficients for prevalence and hazard, respectively.

638 P , prevalence; BY, birth year; DY, diagnostic year.

Time-to-Event Prevalence Estimation

646 **Table 2. Simulation results of parameter optimization using Monte Carlo with**

647 **binomial sampling, 1000 iterations.**

650 β_P , β_h are coefficients for prevalence and hazard, respectively.

651 P, prevalence; BY, birth year; DY, diagnostic year.

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

Table 3. Comparison of the effect of the choice of assumed AE^* **vs. true value of**

665 AE, age of complete eligibility. True values: $\beta_P = 0.1$, $\beta_h = 0$, $P = 0.01$ at the final 666 BY, h = 0.25 at the final DY, $AE = 3$. Maximum age $M = 10$. 20 successive cohorts. 667 Diagnostic pressure is consistent across cases at each DY. Simulation uses real 668 values, no sampling.

669

670 Table 4 shows results with an intentional mismatch between estimation assuming one 671 homogeneous group and data representing two subgroups with different values of *,* 672 illustrated in Fig 5. Note the visible error of the exponential fit to the data at age $=$ 3 and 673 a good fit for age > 3. In this synthetic dataset, the two subgroups are of equal size, and 674 the true value of h in one group is twice that of the other. This information is not known 675 to the estimation, and the data do not indicate subgroup size nor membership. In the 676 worst case, estimation uses $AE^* = AE = 3$, and the $\widehat{\beta_P}$ bias is 0.001, which is 1% of the 677 actual value of 0.1. This error is due to the subgroups having different hazards, which

Time-to-Event Prevalence Estimation

- 678 are not accounted for in the estimation. When using $AF^* = 4$ or $AF^* = 5$, the $\widehat{\beta_P}$ bias
- 679 becomes 6×10^{-4} or less, and model fit is improved (not shown).
- 680
- 681 **Table 4. Comparison of the effect of the choice of assumed** AE* **vs. true value of**

682 AE **= 3, with two unidentified subgroups with different hazards, mismatched to**

683 **analysis.**

684 AE, age of complete eligibility. True values: $\beta_P = 0.1$, $\beta_h = 0$, $P = 0.01$ at the final 685 BY, h = 0.25 at the final DY, $AE = 3$. Two equal-sized groups of cases where the 686 diagnostic pressure h of one group is twice that of the other, while the estimation 687 **assumes one homogeneous group. Maximum age** $M = 10$ **. 20 successive** 688 cohorts. Simulation uses real values, no sampling.

⁶⁸⁹ **Discussion**

690 Readers may suspect that the estimates are unidentified, i.e., not unique, due to

691 possible interaction between age, diagnostic year, and birth year, such that estimates

692 may be biased even if the model fit is excellent. While that concern is appropriate for

693 analytical methods that assume an age distribution, ignore it, or estimate it

Time-to-Event Prevalence Estimation

Time-to-Event Prevalence Estimation

sufficient cause, and various outcomes may serve as events of interest. It is important

Time-to-Event Prevalence Estimation

- to ensure that the eligibility function with respect to the time origin is consistent across
- cohorts.
-
- Investigators may utilize domain knowledge to inform specialized analyses. For
- example, they may incorporate knowledge of mortality rates and standardized mortality
- ratios, rates of recovery from the condition before diagnosis, or the characteristics of
- migration in and out of the study region.

Acknowledgments

- The author thanks Dr. Lu Tian for his expert advice on survival analysis methods; Dr.
- Lorene Nelson and Dr. Kristin Sainani for guidance on my thesis which was the genesis
- of this project and for comments on this paper; Dr. Michael Sigman and Dr. Larry Tang
- for their thoughtful reviews of the paper; and the Stanford Biomedical Data Science
- team for their project reviews and insightful comments.

References

- 1. Szklo M, Nieto FJ. Epidemiology Beyond the Basics. 1st ed. Burlington (MA): Jones & Bartlett; 2014.
- 2. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed*.* Philadelphia: Wolters Kluwer; 2008.

Time-to-Event Prevalence Estimation

- 3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global,
- regional, and national incidence, prevalence, and years lived with disability for 354
- diseases and injuries for 195 countries and territories, 1990–2017: a systematic
- analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858.
- Suppl 1.
- 4. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The
- epidemiology and global burden of autism spectrum disorders. Psychol Med*.*
- 2015;45(3):601–613.
- 5. Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, Six Sites, United States, 2000.
- MMWR Surveillance Summaries*.* 2007; 56(SS01);1-11. Available from:
- https://www.cdc.gov/mmwr/index.html.
- 6. Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, Six Sites, United States, 2002.
- MMWR Surveillance Summaries*.* 2007; 56(SS01);12-28.
- 771 7. Centers for Disease Control. Brief Update: Prevalence of Autism Spectrum
- Disorders Autism and Developmental Disabilities Monitoring Network, United
- States, 2004. MMWR Surveillance Summaries*.* 2009; 58(SS-10);21-24.
- 8. Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, United States, 2006. MMWR
- Surveillance Summaries*.* 2009; 58(SS-10);1-20.

Time-to-Event Prevalence Estimation

- 9. Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008.
- MMWR Surveillance Summaries*.* 2012;61(SS-3):1-19.
- 10.Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010.
- MMWR Surveillance Summaries*.* 2014;63(SS-2):1-21.
- 11.Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012.
- MMWR Surveillance Summaries*.* 2018;65(13):1-23.
- 12.Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014.
- MMWR Surveillance Summaries. 2018;67(6):1-23.
- 13.Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism
- and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016.
- MMWR Surveillance Summaries*.* 2020;69(4):1-12.
- 14.Croen LA, Grether JK, Hoogstrate J, Selvin S. The Changing Prevalence of Autism in California. J Autism Dev Disord. 2002;32(3):207-215.
- 15.Hansen SN, Overgaard M, Andersen PK, Parner ET. Estimating a population
- cumulative incidence under calendar time trends. BMC Med Res Methodol.
- 2017;17:7.

Time-to-Event Prevalence Estimation

- 16.Nevison C, Blaxill M, Zahorodny W. California Autism Prevalence Trends from 1931
- to 2014 and Comparison to National ASD data from IDEA and ADDM. J Autism Dev
- Disord. 2018; (doi.org/10.1007/s10803-018-3670-2). Suppl S1.
- 17.Elsabbagh M, Divan G, Koh Y-J, Kim YS, Kauchali S, Marcin C, et al. Global
- prevalence of autism and other pervasive developmental disorders. Autism
- Research. 2012;5:160–179.
- 18.Campbell CA, Davarya S, Elsabbagh M, Madden L, Fombonne E. Prevalence and
- 804 the Controversy. In: Matson JL, Sturmey P, editors. International Handbook of
- Autism and Pervasive Developmental Disorders*.* New York: Springer; 2011 pp. 25-

35.

- 19.Schisterman EF, Cole SR, Platt RW. Overadjustment Bias and Unnecessary
- Adjustment in Epidemiologic Studies. Epidemiology. 2009;20(4):488-495.
- 20.Keyes KM, Susser E, Cheslack-Postava K, Fountain C, Liu K, Bearman PS. Cohort
- effects explain the increase in autism diagnosis among children born from 1992 to
- 2003 in California. Int J Epidemiol. 2012;41(2):495-503
- 21.Spiers N. Cohort effects explain the increase in autism diagnosis among children
- born from 1992 to 2003 in California [letter]. Int J Epidemiol. 2013;42:1520–1521.
- 22.King M, Bearman P. Diagnostic change and the increased prevalence of autism. Int
- J Epidemiol*.* 2009; 38:1224–1234.
- 23.Rodgers WL. Estimable Functions of Age, Period, and Cohort Effects. Am Sociol
- Rev. 1982;47(6):774-787.

Time-to-Event Prevalence Estimation

- 24.O'Brien RM. Age-Period-Cohort Models. Boca Raton (FL): CRC Press; 2015.
- 25.MacInnis AG. Autism Prevalence Trends by Birth Year and Diagnostic Year:
- Indicators of Etiologic and Non-Etiologic Factors an Age Period Cohort Problem
- 821 [thesis]. Stanford (CA): Stanford University; 2017 DOI:
- 10.13140/RG.2.2.11821.59360. Available from:
- https://www.researchgate.net/publication/322724736_Thesis_Autism_Prevalence_Tr
- 824 ends by Birth Year and Diagnostic Year Indicators of Etiologic and Non-
- 825 Etiologic Factors an Age Period Cohort Problem.
- 26.McKenzie K, Milton M, Smith G, Ouellete-Kuntz H. Systematic Review of the
- Prevalence and Incidence of Intellectual Disabilities: Current Trends and Issues. Cur
- Dev Disord Rep. 2016;3:104-115.
- 27.Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res*.*
- 2009;65(6):591-598.
- 28.MacInnis AG. Time-to-event Prevalence Estimation TTEPE [software]. 2020. OSF
- 832 repository. Available from: https://doi.org/10.17605/OSF.IO/WPNKU.
- 29.Findley DF. Counterexamples to Parsimony and BIC. Ann Inst Stat Math.
- 1991;43(3):505-514.
- 30.Cox DR. Regression Models and Life Tables. J R Stat Soc Series B Stat Methodol*.*
- 1972;34(2):187-220.
- 31.Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed.
- Hoboken (NJ): Wiley; 2002.

Time-to-Event Prevalence Estimation

- 32.Hyman SL, Levy SE, Myers SM, AAP COUNCIL ON CHILDREN WITH
- DISABILITIES, SECTION ON DEVELOPMENTAL AND BEHAVIORAL
- PEDIATRICS. Identification, Evaluation, and Management of Children With Autism
- Spectrum Disorder. Pediatrics. 2020;145(1):e20193447. doi: 10.1542/peds.2019-
- 3447.
- 33.Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed.
- Hoboken (NJ): Wiley; 2013.
- 34.Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical
- methods. Stat Med. 2019;38:2074–2102.